Elevance Health, Inc. (NYSE:ELV) Receives $407.05 Average Price Target from Brokerages

Shares of Elevance Health, Inc. (NYSE:ELV) have been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are covering the firm, MarketBeat Ratings reports. Nine analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $416.1053.

A number of brokerages recently weighed in on ELV. UBS Group increased their price target on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Leerink Partners set a $364.00 target price on shares of Elevance Health in a research report on Thursday, April 23rd. Morgan Stanley increased their price target on shares of Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a report on Thursday, June 4th. Citigroup raised shares of Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group dropped their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th.

Elevance Health Price Performance

Shares of NYSE ELV opened at $422.38 on Wednesday. Elevance Health has a 1-year low of $273.71 and a 1-year high of $426.66. The company has a market cap of $91.72 billion, a price-to-earnings ratio of 18.02, a price-to-earnings-growth ratio of 2.36 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock’s 50-day moving average is $360.00 and its two-hundred day moving average is $343.26.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the firm earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts forecast that Elevance Health will post 26.94 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is 29.26%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Sei Investments Co. boosted its stake in shares of Elevance Health by 7.7% during the second quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after acquiring an additional 11,745 shares during the last quarter. Glenview Trust co raised its position in shares of Elevance Health by 41.5% in the second quarter. Glenview Trust co now owns 1,619 shares of the company’s stock valued at $630,000 after buying an additional 475 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Elevance Health by 6.9% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock worth $25,650,000 after acquiring an additional 4,272 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Elevance Health by 5.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock worth $16,478,000 after buying an additional 2,012 shares during the period. Finally, Quantinno Capital Management LP lifted its position in Elevance Health by 111.8% during the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock valued at $17,080,000 after buying an additional 23,180 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.